Allogene Therapeutics
ALLO • NASDAQ
Allogene Therapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO David D. Chang, with a market cap of $550.9M.
CEODavid D. Chang
Next Earnings
Upcoming earnings announcement for Allogene Therapeutics
Date
Tuesday, May 12, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.19
Revenue Estimate
$2.2K
Earnings History
Past 12 earnings reports for Allogene Therapeutics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 12, 2026 | Q4 2025 | -$0.17Est: -$0.23 | +26.1% | -Est: $2.0K | -100.0% |  10-K |
| Nov 6, 2025 | Q3 2025 | -$0.19Est: -$0.23 | +17.4% | -Est: $1.8K | -100.0% | 10-Q |
| Aug 13, 2025 | Q2 2025 | -$0.23Est: -$0.27 | +14.8% | - | — | 10-Q |
| May 13, 2025 | Q1 2025 | -$0.28Est: -$0.29 | +3.4% | -Est: $1.7K | -100.0% | 10-Q |
| Mar 13, 2025 | Q4 2024 | -$0.28Est: -$0.34 | +17.6% | -Est: $14.0K | -100.0% | 10-K |
| Nov 7, 2024 | Q3 2024 | -$0.32Est: -$0.33 | +3.0% | -Est: $10.0K | -100.0% | 10-Q |
| Aug 7, 2024 | Q2 2024 | -$0.35Est: -$0.35 | 0.0% | -Est: $20.0K | -100.0% | 10-Q |
| May 13, 2024 | Q1 2024 | -$0.38Est: -$0.41 | +7.3% | $22.0KEst: $10.0K | +120.0% | 10-Q |
| Mar 14, 2024 | Q4 2023 | -$0.43Est: -$0.45 | +4.4% | $21.0KEst: $20.0K | +5.0% | 10-K/A |
| Nov 2, 2023 | Q3 2023 | -$0.37Est: -$0.52 | +28.8% | $43.0KEst: $10.0K | +330.0% | — |
| Aug 2, 2023 | Q2 2023 | -$0.53Est: -$0.59 | +10.2% | $44.0KEst: $70.0K | -37.1% | — |
| May 3, 2023 | Q1 2023 | -$0.68Est: -$0.62 | -9.7% | $52.0KEst: $10.0K | +420.0% | — |